- Home
- TYRA vs AUTL Comparison
TYRA vs AUTL Comparison
Compare TYRA & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYRA
- AUTL
- Stock Information
- Founded
- TYRA 2018
- AUTL 2014
- Country
- TYRA United States
- AUTL United Kingdom
- Employees
- TYRA N/A
- AUTL N/A
- Industry
- TYRA Biotechnology: Pharmaceutical Preparations
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TYRA Health Care
- AUTL Health Care
- Exchange
- TYRA Nasdaq
- AUTL Nasdaq
- Market Cap
- TYRA 571.9M
- AUTL 625.4M
- IPO Year
- TYRA 2021
- AUTL 2018
- Fundamental
- Price
- TYRA $11.71
- AUTL $1.75
- Analyst Decision
- TYRA Strong Buy
- AUTL Strong Buy
- Analyst Count
- TYRA 7
- AUTL 5
- Target Price
- TYRA $30.43
- AUTL $9.12
- AVG Volume (30 Days)
- TYRA 201.1K
- AUTL 2.7M
- Earning Date
- TYRA 08-14-2025
- AUTL 08-12-2025
- Dividend Yield
- TYRA N/A
- AUTL N/A
- EPS Growth
- TYRA N/A
- AUTL N/A
- EPS
- TYRA N/A
- AUTL N/A
- Revenue
- TYRA N/A
- AUTL $29,934,000.00
- Revenue This Year
- TYRA N/A
- AUTL $472.28
- Revenue Next Year
- TYRA N/A
- AUTL $114.92
- P/E Ratio
- TYRA N/A
- AUTL N/A
- Revenue Growth
- TYRA N/A
- AUTL 185.17
- 52 Week Low
- TYRA $6.42
- AUTL $1.11
- 52 Week High
- TYRA $29.60
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- TYRA 61.31
- AUTL 32.10
- Support Level
- TYRA $9.96
- AUTL $1.70
- Resistance Level
- TYRA $11.48
- AUTL $1.89
- Average True Range (ATR)
- TYRA 0.73
- AUTL 0.15
- MACD
- TYRA 0.06
- AUTL -0.06
- Stochastic Oscillator
- TYRA 75.43
- AUTL 11.49
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.